Prognostic Value of International Normalized Ratio in Ischemic Stroke Patients without Atrial Fibrillation or Anticoagulation Therapy

Xuewei Xie¹⁴, Xianwei Wang¹⁴, Zixiao Li¹⁴, Xingquan Zhao¹⁴, Zhongrong Miao¹⁵, Liping Liu¹⁴, Hao Li¹⁴, Xia Meng¹⁴, Yongjun Wang¹⁴ and Yilong Wang¹⁴

Xuewei Xie and Xianwei Wang contributed equally to this work.

¹ Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
² China National Clinical Research Center for Neurological Diseases, Beijing, China
³ Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
⁴ Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease Beijing, China
⁵ Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

Aim: The impact of international normalized ratio (INR) on prognosis after acute ischemic stroke without anticoagulation therapy is unclear. Herein, the association between baseline INR and stroke outcomes in patients without anticoagulation therapy was investigated.

Methods: A total of 14,782 ischemic stroke patients from the China National Stroke Registry II were included in this analysis. The period of follow-up was 1 year after stroke onset. Multivariate logistic regression models were used to estimate the relationship between INR and stroke outcomes including all-cause death, recurrent stroke, composite end point, and poor functional outcome.

Results: Of 14,782 patients with stroke, all-cause death occurred in 1080 (7.3%), recurrence stroke in 538 (3.9%), combined end point in 1319 (8.9%), and poor functional outcome in 3001 (20.3%). Compared with the medium INR group (0.9–1.1), the odds ratios with confidence intervals of 95% for the high INR group (>1.1) were 1.58 (1.32–1.98) for all-cause death, 1.40 (1.10–1.79) for stroke recurrence, 1.52 (1.29–1.79) for combined end point, and 1.21 (1.06–1.39) for poor functional outcome. No association between low INR (<0.9) and any stroke outcomes was found compared with the medium group.

Conclusions: Increased admission INR was associated with adverse stroke outcomes among acute ischemic stroke patients without atrial fibrillation or anticoagulation therapy.

Key words: Transient ischemic attack, Minor stroke, International normalized ratio, Recurrent stroke, Registries

Introduction

Of all neurological conditions, stroke is one of the most devastating disease¹. Almost one half of stroke survivors remain disabled, and a seventh requires the institutional care². The INR standardizing the prothrombin time has been accepted as a sensitive and reliable marker of coagulation abnormalities³, and is widely used in the management of patients receiving anticoagulation treatment⁴, ⁵. Changes in blood coagulation function may accelerate blood clot formation or may influence clinical outcome in acute ischemic stroke patients with atrial fibrillation (AF), especially under the anticoagulation therapy⁶,⁷. Yet, it is critical to understand the potential mechanism, which is related to the self-protection in an attempt to avoid excessive brain injury after acute ischemic stroke⁸.
Some studies found that the increased admission INR was an independent predictor of poor clinical outcomes in trauma, acute decompensated heart failure, and acute pulmonary embolism patients. Some researchers explored the relation between admission INR and acute infarct volume in ischemic stroke patients with preadmission warfarin use. However, the instantaneous change of INR after cerebral ischemia was not understood. On the other hand, the prognostic value of INR among ischemic stroke patients without AF or without anticoagulation has not been investigated so far. We assumed that the INR would also have a prognostic value in ischemic stroke patients without AF. Thus, the goal of the current study was to explore the clinical significance and prognostic value of admission INR on adverse stroke outcomes including all-cause death, recurrent stroke, combined end point, and poor functional outcome in patients with acute ischemic cerebrovascular events based on the China national stroke registry phase II.

Methods

Study Design and Participants

The population used for this study was from China National Stroke Registry II (CNSR II). The CNSR II design was described in detail previously. Briefly, the CNSR II launched in 2012 is a nationwide initiative to establish a reliable national stroke database for evaluating stroke care delivery in clinical practice and identifying areas that need further improvement compared with CNSR I in 2007. Of 25,018 patients participated in CNSR II, 14,782 patients without anticoagulation therapy were eligible for the current study after excluding hemorrhagic stroke, medical history of AF or diagnosis of AF at discharge, anticoagulation therapy during hospitalization, missing or extreme INR value (an INR > 5.00 is considered as extreme value, n = 2,880), and loss to 1-year follow-up (n = 2,008) (Supplementary Fig. 1). The study was approved by the central Institutional Review Board at Beijing Tiantan Hospital, in compliance with the Declaration of Helsinki. Every participant provided signed informed consent before his/her participation.

Data Collection

Trained research coordinators in each hospital collected the baseline data including patient demographics, vascular risk factors, stroke severity, lab test, medication use, complication, and diagnosis at discharge. The vascular risk factors included the history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, and moderate or heavy alcohol consumption (≥ 2 standardized alcohol drinks per day). The hypertension was defined as systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, any use of continuous antihypertensive drug for more than 2 weeks before the onset of cerebrovascular diseases, or self-reported history of hypertension. The dyslipidemia was defined as serum triglyceride ≥ 150 mg/dL, low-density lipoprotein cholesterol ≥ 130 mg/dL, high-density lipoprotein cholesterol ≤ 40 mg/dL, any use of lipid-lowering drugs, or any self-reported history of dyslipidemia. The diabetes mellitus was defined as fasting glucose level ≥ 7.0 mmol/L (126 mg/dL), the nonfasting glucose concentration ≥ 11.1 mmol/L (200 mg/dL) with classic symptoms of hyperglycemia or hyperglycemic crisis, any use of glucose-lowering drugs, or any self-reported history of diabetes mellitus. The height and weight were measured with participants wearing a scrub suit and no shoes, and then the body mass index (BMI) was calculated by dividing the weight in kilograms at the square of height in meters.

Measurements of INR

The venous blood was drawn from patients who fasted within the first 24 h of admission for routine laboratory measurements including INR. The blood samples were obtained, preserved, and processed in a manner recommended by the clinical site laboratory’s policies and procedures. The 3.2%citrate tubes are used and filled properly to maintain a blood/citrate ratio of 9/1. INR was measured on a STA-R EVOLUTION automated coagulation analyzer (Diagnostica Stago, Asnières, France) with an international sensitivity index of approximately 1.0 and using HemosIL RecombiPlasTin 2G as reagent (Instrumentation Laboratory, Bedford, MA, USA). The reference range of INR was roughly 0.9–1.1 in all clinical laboratories.

Study Outcomes

The participants were followed up by telephone interview by trained research personnel who were blinded to patient baseline clinical status. The patients were asked standardized follow-up questions 12 months after the onset of stroke. The study outcomes included the all-cause mortality, stroke recurrence, and poor functional outcome. Death was confirmed either by the death certificates from local citizen registries or from the treating hospitals. If such records were unavailable, the death was confirmed if it was reported on 2 consecutive follow-up contacts with ≥ 2 different proxies. The recurrent stroke included the ischemic stroke, intracranial hemorrhage, and subarachnoid hemorrhage. The recurrent end points of the stroke...
comprised fatal and nonfatal stroke. We also evaluated the composite of death or recurrent stroke in the prognostic analysis. The poor functional outcome was defined as the modified Rankin Scale ranging from 3 to 6.

**Statistical Analysis**

The subjects were divided into the following three groups based on the reference range of INR - low INR (<0.9), medium INR group (0.9–1.1), and high INR (>1.1). The baseline characteristics were compared between the three INR groups. The continuous variables were expressed as mean (SD) or median (interquartile range, IQR) values, and compared using the analysis of variance or Kruskal–Wallis test. The categorical variables were expressed as frequency (percent), and compared using the chi-square test.

The multivariable logistic regression models were used to assess the association of INR with 12-month clinical outcomes in stroke patients. The covariates in the multivariable analysis included the age, sex, history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, moderate or heavy alcohol consumption, BMI, admission NIHSS and mRS scores, pneumonia, antihypertensive, anti-diabetic and lipid-lowering therapy, as well as the time from onset to the blood sampling. The odds ratios (ORs) were calculated with confidence intervals (CIs) of 95% for low and high INR groups compared to the medium group.

To explore the association between INR distribution and clinical outcomes, the INR grading categories were created by 0.05 increments i.e., ≤ 0.85, 0.85–0.90, 0.90–0.95, 0.95–1.00, 1.00–1.05, 1.05–1.10, 1.10–1.15, 1.15–1.20, and > 1.20. The adjusted OR and 95% CIs were assessed for each category using an INR value of 0.95–1.00 as the reference group. Additionally, we performed a sensitivity analysis in a subgroup of patients without intravenous (IV) recombinant tissue plasminogen activator (rtPA) treatment, because the current guidelines accept IV rtPA treatment for patients treated within 4.5 h of onset with an INR ≤ 1.715.

All analyses were conducted with SAS Version 9.2 software (SAS Institute). Two-tailed P values <0.05 were considered to be statistically significant.

**Results**

**Baseline Characteristics**

A total of 14,782 patients without anticoagulation therapy were eligible for our study (Supplementary Fig. 1). Supplementary Table 1 shows the baseline characteristics of ischemic patients included and excluded due to missing INR or 1-year follow-up. The baseline characteristics of patients included in this study and those from CNSR II were basically similar, except the patients included in this subgroup analysis for which higher prevalence of vascular risk factors including history of stroke, dyslipidemia, diabetes mellitus, coronary heart disease, and moderate or heavy drinking was noticed. More patients included in this study had a mRS score of 3-5 at discharge (Supplementary Table 1). The demographic and clinical characteristics of eligible patients are shown in Table 1. As compared with those with the low INR, the patients with high INR were more likely to be older, male, to have higher prevalence of history of stroke and coronary heart disease, pneumonia, shorter time from symptom onset to the blood sampling, higher discharge mRS score, and higher NIHSS on admission, whereas the prevalence of hypertension, diabetes mellitus, and medications (antihypertensive, antidiabetic, and lipid-lowering), and BMI were lower in patients with high INR than those with low INR.

**One-Year Rates of Adverse Stroke Outcomes**

Table 2 summarizes the 1-year incidences of stroke outcomes including all-cause death, stroke recurrence, composite outcome of death and stroke recurrence, and poor functional outcome. Of 14,782 patients with stroke, all-cause death occurred in 1080 (7.3%), recurrence stroke in 538 (3.9%), combined end point in 1319 (8.9%), and poor functional outcome in 3001 (20.3%). The incidence of all outcomes increased in INR groups (P<0.001 for all). The incidence of both ischemic stroke and intracranial hemorrhage also increased in INR groups (P<0.001 for ischemic stroke, P=0.01 for intracranial hemorrhage). Supplementary Fig.2 displays 1-year events rate in INR grading categories. The risk of all-cause death, recurrent stroke, combined end point, and poor functional outcome was obviously increased for the INR grading category of 1.05–1.10 and higher.

**Association between INR and Clinical Outcomes**

Table 3 shows the associations between the INR groups and all stroke outcomes. The adjusted ORs with 95% CIs for high vs medium INR were 1.58 (1.32–1.98) for all-cause death, 1.40 (1.10–1.79) for stroke recurrence, 1.52 (1.29–1.79) for combined end point, and 1.21 (1.06–1.39) for poor functional outcome. The adjusted ORs with 95% CIs for low vs medium INR were 0.93 (0.73–1.19) for all-cause mortality, 0.80 (0.58–1.09) for stroke recurrence, 0.87 (0.70–1.07) for combined end point, and 0.89 (0.76–1.04) for poor functional outcome.

Fig.1 shows that the adjusted ORs for all-cause
Table 1. Baseline characteristics of the participants to the study classified based on the admission INR value

| Characteristics | Total \( n = 14782 \) | INR < 0.9 \( n = 2137 \) | INR = 0.9–1.1 \( n = 10563 \) | INR > 1.1 \( n = 2082 \) | \( P \)-value |
|-----------------|----------------------|---------------------|---------------------|---------------------|-------------|
| **Age, years, mean (SD)** | 64.2 (11.9) | 61.8 (11.2) | 64.3 (11.9) | 66.2 (12.0) | <0.001 |
| **Male** | 9511 (64.3) | 1243 (58.2) | 6863 (64.7) | 1432 (68.8) | <0.001 |
| **INR, mean (SD)** | 1.01 (0.18) | 0.85 (0.05) | 0.99 (0.06) | 1.26 (0.33) | <0.001 |
| **ALT, U/L, median (IQR)** | 19 (13–27) | 20 (14–29) | 18 (13–26) | 18 (13–26) | <0.001 |
| **AST, U/L, median (IQR)** | 21 (17–26) | 21 (17–27) | 20 (17–26) | 21 (17–28) | <0.001 |
| **Vascular risk factors, \( n \) (%)** | | | | | |
| **Stroke** | 5283 (35.7) | 696 (32.6) | 3812 (36.1) | 775 (37.2) | 0.003 |
| **Hypertension** | 11218 (75.9) | 1661 (77.7) | 8033 (76.0) | 1524 (73.2) | 0.002 |
| **Dyslipidemia** | 1844 (12.5) | 276 (12.9) | 1319 (12.5) | 249 (12.0) | 0.64 |
| **Diabetes mellitus** | 3081 (20.8) | 506 (23.7) | 2221 (21.0) | 354 (17.0) | <0.001 |
| **Coronary heart disease** | 1772 (12.0) | 242 (11.3) | 1252 (11.9) | 278 (13.4) | 0.09 |
| **Current or previous smoking** | 6655 (45.0) | 923 (43.2) | 4770 (45.2) | 962 (46.2) | 0.72 |
| **Moderate or heavy drinkers** | 4548 (30.8) | 632 (29.6) | 3273 (31.0) | 642 (30.8) | 0.46 |
| **Discharge mRS score = 3–5, \( n \) (%)** | 3076 (20.8) | 351 (16.4) | 2213 (21.0) | 512 (24.6) | <0.001 |
| **BMI, kg/m\(^2\), median (IQR)** | 24.1 (22.1–25.8) | 24.1 (22.3–26.0) | 24.1 (22.2–25.8) | 23.8 (21.7–25.6) | <0.001 |
| **Mean time to blood collection, hour, median (IQR)** | 43 (24–72) | 45 (25–84) | 43 (24–72) | 40 (24–71) | <0.001 |
| **Admission NIHSS score, median (IQR)** | 3 (1–6) | 3 (1–5) | 3 (1–6) | 4 (1–7) | <0.001 |
| **Medications, \( n \) (%)** | | | | | |
| **Antithrombotic** | 12249 (82.9) | 1871 (87.6) | 8642 (81.8) | 1736 (83.4) | <0.001 |
| **Diabetes therapy** | 7242 (49.0) | 1081 (50.6) | 5202 (49.2) | 959 (46.1) | 0.008 |
| **Antidiabetic** | 3017 (20.4) | 516 (24.1) | 2192 (20.8) | 309 (14.8) | <0.001 |
| **Lipid-lowering** | 7848 (53.1) | 1286 (60.2) | 5626 (53.3) | 936 (45.0) | <0.001 |
| **Pneumonia, \( n \) (%)** | 868 (5.9) | 82 (3.8) | 585 (5.5) | 201 (9.7) | <0.001 |

Abbreviations IN-international normalized ratio, ALT-alanine transaminase, AST-aspartate transaminase, mRS-modified Rankin Scale, NIHSS-National Institutes of Health Stroke Scale.

Table 2. Events rate at 1 year in participants classified based on the admission INR value

| Outcomes | Total \( n = 14782 \) | INR < 0.9 \( n = 2137 \) | INR = 0.9–1.1 \( n = 10563 \) | INR > 1.1 \( n = 2082 \) | \( P \)-value |
|----------|----------------------|---------------------|---------------------|---------------------|-------------|
| **All-cause death** | 1080/14767 (7.3) | 99/2136 (4.6) | 713/10551 (6.8) | 268/2080 (12.9) | <0.001 |
| **Recurrent Stroke** | 538/13788 (3.9) | 50/2030 (2.5) | 380/9907 (3.8) | 108/1851 (5.8) | <0.001 |
| **Ischemic Stroke** | 510/13788 (3.7) | 47/2030 (2.3) | 365/9907 (3.7) | 98/1851 (5.3) | <0.001 |
| **Intracranial hemorrhage** | 28/13788 (0.2) | 3/2030 (0.2) | 15/9907 (0.2) | 10/1851 (0.5) | 0.01 |
| **Combined end point** | 1319/14782 (8.9) | 121/2137 (5.7) | 889/10563 (8.4) | 309/2082 (14.8) | <0.001 |
| **Poor functional outcome** | 3001/14767 (20.3) | 315/2136 (14.7) | 2114/10551 (20.0) | 572/2080 (27.5) | <0.001 |

Abbreviations INR - international normalized ratio.

The high INR (> 1.1) was independent of all the stroke outcomes in the subgroup of patients without IV rtPA treatment, which was consistent with the primary analysis. The multivariable analysis showed that the ORs with 95% CIs for the high vs medium INR were 1.61 (1.34–1.95) for all-cause death, 1.46 (1.14–1.87) for stroke recurrence, 1.55 (1.31–1.83) for combined end point, and 1.25 (1.08–1.44) for poor functional outcome. No association between low INR (< 0.9) and any stroke outcomes was found compared with the medium group.
In this post hoc analysis of the national cohort study of stroke, it was observed that the high INR is associated with increased risk of 1-year all-cause mortality, stroke recurrence, the combined end point, and poor functional outcome compared with medium INR. However, the low INR did not have a significant impact on the all stroke outcomes. In INR grading categories, only relationships between the all-cause death and combined end point with the elevated grading increment of INR remained significant, although the rates of all stroke outcomes increased with the increase in INR increment. To the best of our knowledge, this is the first national study that defines the prognostic value of baseline INR in patients with ischemic cerebrovascular events.

Discussion

In this post hoc analysis of the national cohort study of stroke, it was observed that the high INR is associated with increased risk of 1-year all-cause mortality, stroke recurrence, the combined end point, and poor functional outcome compared with medium INR. However, the low INR did not have a significant impact on the all stroke outcomes. In INR grading categories, only relationships between the all-cause death and combined end point with the elevated grading increment of INR remained significant, although the rates of all stroke outcomes increased with the increase in INR increment. To the best of our knowledge, this is the first national study that defines the prognostic value of baseline INR in patients with ischemic cerebrovascular events.
It was noticed that compared with median INR, the high INR was significantly associated with the high risk of 1-year stroke outcomes including all-cause mortality, stroke recurrence, combined end point, and poor functional outcome. In previously published studies, the association between elevated baseline INR and poor outcomes in patients with acute decompensated heart failure and acute pulmonary embolism was investigated\(^{10,11}\). A plausible explanation for this phenomenon might be that after an ischemic event, the activation of the coagulation system may result in the consumption of coagulation factors, which is manifested as an elevated INR. Therefore, the thrombosis could be inhibited. In this condition, either the blood clot enlargement is prevented or thrombolysis is stimulated to increase the blood flow perfusion to the distal vessel in patients after stroke onset\(^{16}\). In this analysis, the patients with higher INR had a more serious stroke measured by the baseline NIHSS score (Supplementary Table 3). Our results suggest that the admission INR would be an important index for prognosis in stroke patients and might be a therapeutic target in those without AF.

It was also found a high risk of all-cause death and combined end point in patients with INR grading category \(>1.05\), with 0.05 increments, as compared with those with INR from 0.95 to 1.00. This result supports the feasibility of considering INR, divided in three groups, for patients with ischemic cerebrovascular events. Yet, no significant association between INR value and stroke recurrence or poor functional outcome was observed. This could be explained by the relative few events occurring in each group, which could enlarge the confidence interval.

In addition, a low INR had a minor risk reduction in all stroke outcomes. As compared with INR of 0.95–1.00, none of low INR grading categories was meaningfully associated with any stroke outcomes. The reason for this phenomenon is that the baseline INR was barely increased, because the activation of anticoagulation system was low after minor ischemic cerebrovascular events onset. However, another unknown mechanism cannot be excluded to interpret this result.

It should be recognized that this study had some limitations, which are listed in the following. First, it was an observational study, which limited the possibility to make causal inferences. Secondly, the diffusion-weighted imaging lesion volume measurements were not performed to determine the relationship between INR and brain infarct size. Thus, the association between INR and cerebral infarct size was not considered in this study. Thirdly, the association between INR and outcomes based on the subtypes of ischemic stroke was not evaluated, because there are no data on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) subtypes or other classification of ischemic stroke subtypes. Furthermore, the patients with cardioembolic stroke were excluded from the current study due to the treatment with anticoagulant drugs. Finally, our cohort included exclusively Chinese patients. Hence, the results may not be generalized to other ethnic populations with cerebrovascular events.

**Conclusions**

In patients with acute ischemic stroke, increased baseline INR in the absence of anticoagulation was an independent predictor of 1-year all-cause mortality, stroke recurrence, combined end point, and poor functional outcome. These findings might suggest the importance of INR evaluation in clinical practice in acute ischemic stroke patients both with and without preadmission anticoagulant use. Nevertheless, further investigation would be necessary to verify and confirm the relationship between INR and clinical outcomes of stroke.

**Acknowledgments**

We thank all participating hospitals, their physicians and nurses, and the CNSR II Steering Committee members.

**Funding**

Funding for this study was provided by the National Key R&D Program of China (2016YFC1307300, 2016YFC1307301, 2017YFC1310900 and 2017YFC1310901).

**Contributors**

Yilong Wang, Yongjun Wang, and Xingquan Zhao conceived and designed the study. Xuwei Xie, Xianwei Wang, and Yilong Wang interpreted the data and prepared the report. Yongjun Wang, Liping Liu, and Zhongrong Miao contributed to the comments on the draft manuscript and revised the report. Zixiao Li and Xia Meng coordinated the study. Hao Li and Xiangwei Wang conducted the statistical analysis.

**Disclosure**

The authors report no disclosures relevant to the manuscript.
References

1) Mukherjee D and Patil CG. Epidemiology and the global burden of stroke. World Neurosurg, 2011; 76: S85-90
2) Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ and Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke, 2004; 35: 731-735
3) Ignjatovic V. Prothrombin time/international normalized ratio. Methods Mol Biol, 2013; 992: 121-129
4) Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV and Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 2003; 290: 2685-2692
5) Wazni OM, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, Di Biase L, Martin DO, Kanj M, Arruda M, Cummins J, Schweikert R, Saliba W and Natale A. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation, 2007; 116: 2531-2534
6) Yasaka M, Minematsu K and Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med, 2001; 40: 1183-1188
7) Fletcher AP, Alkjaersig N, Davies A, Lewis M, Brooks J, Hardin W, Landau W and Raichle ME. Blood coagulation and plasma fibrinolytic enzyme system pathophysiology in stroke. Stroke, 1976; 7: 337-348
8) Pikija S, Trkulja V, Mutzenbach JS, McCoy MR, Ganger P and Sellner J. Fibrinogen consumption is related to intracranial clot burden in acute ischemic stroke: a retrospective hyperdense artery study. J Transl Med, 2016; 14: 250
9) Verma A and Kole T. International normalized ratio as a predictor of mortality in trauma patients in India. World J Emerg Med, 2014; 5: 192-195
10) Okada A, Sugano Y, Nagai T, Takashio S, Honda S, Asaumi Y, Aiba T, Noguchi T, Kusano KF, Ogawa H, Yasuda S, Anzai T and Na DEFI. Prognostic Value of Prothrombin Time International Normalized Ratio in Acute Decompensated Heart Failure: A Combined Marker of Hepatic Insufficiency and Hemostatic Abnormality. Circ J, 2016; 80: 913-923
11) Kiris T, Yazici S, Durmus G, Canga Y, Karaca M, Nazli C and Dogan A. The relation between international normalized ratio and mortality in acute pulmonary embolism: A retrospective study. J Clin Lab Anal, 2017
12) Ay H, Arzava EM, Gungor L, Greer D, Singhal AB, Furie KL, Koroshetz WJ and Sorensen AG. Admission international normalized ratio and acute infarct volume in ischemic stroke. Ann Neurol, 2008; 64: 499-506
13) Bettger JP, Li Z, Xian Y, Liu L, Zhao X, Li H, Wang C, Wang C, Meng X, Wang A, Pan Y, Peterson ED, Wang Y, Wang Y and investigators CI. Assessment and provision of rehabilitation among patients hospitalized with acute ischemic stroke in China: Findings from the China National Stroke Registry II. Int J Stroke, 2017; 12: 254-263
14) Wang Y, Cui L, Ji X, Dong Q, Zeng J, Wang Y, Zhou Y, Zhao X, Wang C, Liu L, Nguyen-Huynh MN, Claiborne Johnston S, Wong L, Li H and China National Stroke Registry. The China National Stroke Registry for patients with acute cerebrovascular events: design, rationale, and baseline patient characteristics. Int J Stroke, 2011; 6: 355-361
15) Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW, Jr., Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintemark M, Yonas H, American Heart Association Stroke C, Council on Cardiovascular N, Council on Peripheral Vascular D and Council on Clinical C. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013; 44: 870-947
16) Levi M, van der Poll T and Buller HR. Bidirectional relation between inflammation and coagulation. Circulation, 2004; 109: 2698-2704
Supplementary Table 1. Baseline characteristics of patients included vs. excluded in the study

| Characteristics                        | Patients included (n = 14,782) | Patients excluded (n = 4,868) | P-value |
|----------------------------------------|-------------------------------|-------------------------------|---------|
| Age, years, mean (SD)                  | 64.2 (11.9)                   | 63.8 (11.9)                   | 0.05    |
| Male sex                               | 9511 (64.3)                   | 3096 (63.6)                   | 0.35    |
| Vascular risk factors, n (%)           |                               |                               |         |
| Stroke                                 | 5283 (35.7)                   | 1599 (32.8)                   | <0.001  |
| Hypertension                           | 11218 (75.9)                  | 3657 (75.1)                   | 0.28    |
| Dyslipidemia                           | 1844 (12.5)                   | 547 (11.2)                    | 0.02    |
| Diabetes mellitus                      | 3081 (20.8)                   | 947 (19.5)                    | 0.04    |
| Coronary heart disease                 | 1772 (12.0)                   | 522 (10.7)                    | 0.02    |
| Current or previous smoking            | 6655 (45.0)                   | 2184 (44.9)                   | 0.85    |
| Moderate or heavy drinkers             | 4548 (30.8)                   | 1396 (28.7)                   | 0.01    |
| mRS score of 3-5 at discharge, n (%)   | 3076 (20.8)                   | 928 (19.1)                    | 0.01    |
| Body mass index, kg/m², median (IQR)   | 24.1 (22.1-25.8)              | 24.1 (22.0-25.7)              | 0.38    |
| Time to blood collection, hour, median (IQR) | 43 (24-72)                   | 44 (24-80)                    | 0.94    |
| Admission NIHSS score                  | 3 (1-6)                       | 3 (1-6)                       | 0.05    |
| Medications                            |                               |                               |         |
| Antihypertensive                       | 7242 (49.0)                   | 2423 (49.8)                   | 0.34    |
| Antidiabetic                           | 3017 (20.4)                   | 937 (19.2)                    | 0.08    |
| Lipid-lowering                         | 7848 (53.1)                   | 2629 (54.0)                   | 0.27    |
| Pneumonia                              | 868 (5.9)                     | 275 (5.6)                     | 0.56    |

Abbreviations: mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.

Supplementary Table 2. Adjusted odds ratios and 95% confidence intervals for risk of events according to admission INR value in patients without rtPA treatment

| INR groups                        | INR < 0.9 (n = 1869) | INR: 0.9-1.1 (n = 9292) | INR > 1.1 (n = 1852) |
|-----------------------------------|----------------------|--------------------------|----------------------|
| All-cause death                   | 0.97 (0.75-1.25)     | 1.00                     | 1.61 (1.34-1.95)     |
| Recurrent stroke                  | 0.85 (0.62-1.16)     | 1.00                     | 1.46 (1.14-1.87)     |
| Combined end point                | 0.88 (0.71-1.11)     | 1.00                     | 1.55 (1.31-1.83)     |
| Functional outcome                | 0.93 (0.79-1.10)     | 1.00                     | 1.25 (1.08-1.44)     |

Adjusted for age, sex, history of stroke, hypertension, dyslipidemia, diabetes mellitus, coronary heart disease, current or previous smoking, moderate or heavy alcohol consumption, body mass index, liver function, admission NIHSS, mRS scores at discharge, pneumonia, antiplatelet, antihypertensive, antidiabetic, lipid-lowering therapy and mean time from onset to blood collection.
**Supplementary Table 3.** Associations between INR and baseline patient characteristics using the ordinal logistic regression model

| Characteristics                        | Odds ratios | 95% confidence intervals | P-value |
|----------------------------------------|-------------|--------------------------|---------|
| Age, years                             |             |                          |         |
| ≥ 65 vs. < 65                          | 1.50        | 1.39-1.61                | <0.001  |
| Female vs. male                        | 0.71        | 0.65-0.78                | <0.001  |
| Vascular risk factors                  |             |                          |         |
| Stroke                                 | 1.08        | 1.00-1.17                | 0.046   |
| Hypertension                           | 0.86        | 0.79-0.93                | <0.001  |
| Dyslipidemia                           | 0.99        | 0.89-1.10                | 0.80    |
| Diabetes mellitus                      | 0.81        | 0.74-0.89                | <0.001  |
| Coronary heart disease                 | 1.08        | 0.97-1.20                | 0.18    |
| Current or previous smoking            | 0.93        | 0.85-1.01                | 0.10    |
| Moderate or heavy drinkers             | 1.02        | 0.94-1.11                | 0.66    |
| Body mass index                        | 0.99        | 0.98-1.00                | 0.17    |
| Mean time to blood collection, days    | 0.96        | 0.94-0.98                | <0.001  |
| Admission NIHSS score                  | 1.03        | 1.02-1.04                | <0.001  |

Ordinal logistic regression model was used to evaluate association of INR with baseline patient characteristics. INR was divided into three categories: low INR (< 0.9), medium INR group (0.9 - 1.1), high INR (> 1.1). Abbreviations: INR, international normalized ratio; NIHSS, National Institutes of Health Stroke Scale.

**Supplementary Fig. 1.** Flow chart showing the patients selection from China National Stroke Registry II. AF indicates atrial fibrillation; INR, international normalized ratio.
Supplementary Fig. 2. Rates of one-year events among patients with ischemic stroke or TIA according to INR grading category